Novobiocin Sodium

新生霉素钠

Report date: 2025/06/11 13:56:49
NME

Base Information

Drug NameNovobiocin Sodium
Drug Alias NameStreptonivicin新生霉素NovobiocineNovobiocinaNovobiocinum +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase (DNA) II alpha inhibitorsHeat shock protein HSP90 inhibitors
TargetsTopoisomerase (DNA) II alphaHeat shock protein HSP90
Therapy Area/IndicationsSolid tumoursNeoplasmsBacterial Infections
Global Approved IndicationsBacterial Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1964/09/04
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteVarsity Pharmaceuticals Ltd
Inactive CompaniesDana-Farber Cancer InstitutePharmacia & Upjohn
Active IndicationsSolid tumours
Inactive IndicationsNeoplasmsBacterial Infections

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG